Cargando…
Dysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is increasingly recognized as a systemic disease driven by alteration in the normal functioning of multiple metabolic pathways affecting all of the major carbon substrates, including amino acids. We found that human pulmonary hypertension patients (WHO Group I,...
Autores principales: | Egnatchik, Robert A., Brittain, Evan L., Shah, Amy T., Fares, Wassim H., Ford, H. James, Monahan, Ken, Kang, Christie J., Kocurek, Emily G., Zhu, Shijun, Luong, Thong, Nguyen, Thuy T., Hysinger, Erik, Austin, Eric D., Skala, Melissa C., Young, Jamey D., Roberts, L. Jackson, Hemnes, Anna R., West, James, Fessel, Joshua P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448547/ https://www.ncbi.nlm.nih.gov/pubmed/28680578 http://dx.doi.org/10.1086/690236 |
Ejemplares similares
-
Oxidative injury is a common consequence of BMPR2 mutations
por: Lane, Kirk L., et al.
Publicado: (2011) -
The genetics of pulmonary arterial hypertension in the post-BMPR2 era
por: Fessel, Joshua P., et al.
Publicado: (2011) -
A potential adverse role for leptin and cardiac leptin receptor in the right ventricle in pulmonary arterial hypertension: effect of metformin is BMPR2 mutation-specific
por: Talati, Megha, et al.
Publicado: (2023) -
BMPR2 expression is suppressed by signaling through the estrogen receptor
por: Austin, Eric D, et al.
Publicado: (2012) -
LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small cell lung cancer (NSCLC) cells
por: Whang, Young Mi, et al.
Publicado: (2015)